

Seeing Stars: A review of the white dot syndromes

Andrew Zheng, MD

14 March 2026
Winter Ophthalmic Summit


Objectives

At the end of this talk, audience members should be able to...

1. Appreciate phenotypic differences among the white dot syndromes
2. Possess a cursory understanding of treatment approaches for the white dot syndromes
3. Understand the importance of distinguishing white dot syndromes from infectious masquerades

Introduction

- **White dot syndromes** = a heterogenous collection of posterior uveitides characterized by **white spots and dots** in the retina/choroid
- **Posterior uveitis** involves inflammation in the retina and/or choroid and is generally much more vision-threatening than anterior or intermediate uveitis
- Approximately 30 000 cases of posterior uveitis per year in the US



COLORADO RETINA

OVERVIEW OF IMAGING MODALITIES

Optical coherence tomography (OCT)

Cross-sectional, anatomic/structural view of retina and choroid


- Uses near-IR light to measure reflectance from tissue layers
- Provides high-resolution intraretinal detail and some choroidal detail
- Limited utility for vascular imaging
- Limited field of view (central macula or occasionally mid-periphery)



Fundus photography and autofluorescence (FAF)

Wide-angle two-dimensional views of posterior segment structures

- Optos photos are not true-color (lack a blue channel so image is biased towards red/green)
- Autofluorescence detects RPE, metabolic activity, lipofuscin
- Autofluorescence can highlight lesions that are not readily apparent on photos




Fluorescein angiography (FA)




Great for imaging retina and vasculature, provides less information on choroid

- Light-sensitive, light-emitting dye that illuminates the path of blood flow through the retinal vessels
- Dark **hypofluorescent** findings
 - Blockage from vitreous hemorrhage
 - Areas of ischemia and capillary non-perfusion
- Bright **hyperfluorescent** findings
 - Staining of scars and lesions
 - Leakage in areas of vasculitis, retinal edema, inflammation




Saving Sight and Improving the Lives of our Patients Through Innovation and the Highest Quality Care

Indocyanine green angiography (ICGA)



Great for choroidal vascular imaging

- ICG binds to proteins and is less "leaky" than fluorescein so better for imaging choroidal vessels
- Excitation/emission wavelengths are different from FA and result in less interference from the overlying RPE
- Can show lesions in the choroid as areas of hypocyanescence
- Few side effects than fluorescein



Saving Sight and Improving the Lives of our Patients Through Innovation and the Highest Quality Care


COLORADO RETINA

THE WHITE DOT SYNDROMES

Case 1




41F w/ new onset "speckles of light" in right eye only





Saving Sight and Improving the Lives of our Patients Through Innovation and the Highest Quality Care

Case 1 OCT




Saving Sight and Improving the Lives of our Patients Through Innovation and the Highest Quality Care

Case 1 FAF




Saving Sight and Improving the Lives of our Patients Through Innovation and the Highest Quality Care

Case 1 FA and ICGA



Saving Sight and Improving the Lives of our Patients Through Innovation and the Highest Quality Care


Multiple evanescent white dot syndrome (MEWDS)



- Acute onset, multiple small gray-white dots in deep retina and RPE
- 80% of cases are unilateral and there is a F > M predominance
- Foveal granularity on exam and loss of EZ integrity are characteristic
- Most cases are self-limited and vision recovers well
- Steroids can hasten recovery
- From the neurology literature: AKA idiopathic enlargement of blind spot syndrome


Saving Sight and Improving the Lives of our Patients Through Innovation and the Highest Quality Care

Case 1 Follow-up




Saving Sight and Improving the Lives of our Patients Through Innovation and the Highest Quality Care

Case 2




24M w/ headaches and new vision changes OU





Saving Sight and Improving the Lives of our Patients Through Innovation and the Highest Quality Care

Case 2 OCT




Saving Sight and Improving the Lives of our Patients Through Innovation and the Highest Quality Care

Case 2 FA



Saving Sight and Improving the Lives of our Patients Through Innovation and the Highest Quality Care

Case 2 ICGA



Saving Sight and Improving the Lives of our Patients Through Innovation and the Highest Quality Care


Acute posterior multifocal placoid pigment epitheliopathy (APMPPE)



- Sequential, bilateral onset in young patients (2nd – 3rd decade)
- Male predominance
- Characteristic lesions on FA; "blocks early, hyperfluoresces late"
 - However this is not specific
- Treatment is steroids or observation
- DDX to consider: serpiginous, "ampiginous" (relentless APMPPE)
- Watch for neurologic signs (headaches)
 - Can develop strokes in very rare cases within days to weeks of eye diagnosis
 - Most commonly occur as steroids are being tapered or IMT is being changed


Saving Sight and Improving the Lives of our Patients Through Innovation and the Highest Quality Care

Case 2 Follow-up (2 weeks later)



Saving Sight and Improving the Lives of our Patients Through Innovation and the Highest Quality Care

Case 2 Follow-up (2 weeks later)



Saving Sight and Improving the Lives of our Patients Through Innovation and the Highest Quality Care

Case 3




67F with new onset flashes and floaters OU

Visual Acuity (Snellen - Linear)		
Right	Left	
Dist cc	20/20 -2	
Dist ph cc	20/30 +2	
Tonometry (Tonopen, 1:57 PM)		
Right	Left	
Pressure	12	
Slit Lamp Exam		
	right	Left
Lids/Lashes	Normal lids, lashes, lacrimal glands, and lacrimal drainage	Normal lids, lashes, lacrimal glands, and lacrimal drainage
Conjunctiva/Sclera	White and quiet	White and quiet
Cornea	Normal epithelium, stroma, endothelium, and tear film	Normal epithelium, stroma, endothelium, and tear film
Anterior Chamber	Deep and quiet	Deep and quiet
Iris	dilated	dilated
Lens	1+ NS, 2+ CC	1+ NS, 2+ CC
Vitreous	PVD, 1+ ant vit cell	PVD, trace ant vit cell


Saving Sight and Improving the Lives of our Patients Through Innovation and the Highest Quality Care

Case 3 Photos





Saving Sight and Improving the Lives of our Patients Through Innovation and the Highest Quality Care

Case 3 FA



Saving Sight and Improving the Lives of our Patients Through Innovation and the Highest Quality Care

Case 3 ICGA



Saving Sight and Improving the Lives of our Patients Through Innovation and the Highest Quality Care


Birdshot retinochoroidopathy



- Characteristic **deep, ovoid, creamy lesions** best seen on **ICGA**
- Chronic, **bilateral**, and often recurrent if untreated
- Not generally associated with systemic disease (ocular inflammation only)
- **Female** > male predominance
- Average age at diagnosis in **5 – 6th decade of life**
- **Photopsias, nyctalopia, color vision loss**
- Inflammation (vitritis, disc leakage, vasculitis) → **immunosuppression**

Saving Sight and Improving the Lives of our Patients Through Innovation and the Highest Quality Care

Birdshot retinochoroidopathy



- HLA-A29 is highly sensitive but not specific for birdshot
 - About 8 – 10% of the population is HLA-A29 (+)
 - Only 1 in 10 000 HLA-A29 (+) patients have birdshot
- Also has a retinal degeneration-like component that is often chronic and progressive → follow with exam, imaging, HVF, ERG

Saving Sight and Improving the Lives of our Patients Through Innovation and the Highest Quality Care

HLA-A29 testing in birdshot retinochoroidopathy




If you are HLA-A29 positive, does this mean you have birdshot?




Saving Sight and Improving the Lives of our Patients Through Innovation and the Highest Quality Care

Case 3 ERG



Saving Sight and Improving the Lives of our Patients Through Innovation and the Highest Quality Care



Case 3 Follow-up



Presentation 20/20 Month 2 20/20

Saving Sight and Improving the Lives of our Patients Through Innovation and the Highest Quality Care

Case 3 ERG




Presentation 20/30 Month 2 20/20

Saving Sight and Improving the Lives of our Patients Through Innovation and the Highest Quality Care

Case 4




32F with h/o uveitis presents with increased photopsias OD



2020 IOP 15 2020 IOP 16

Saving Sight and Improving the Lives of our Patients Through Innovation and the Highest Quality Care

Case 4 FAF



Saving Sight and Improving the Lives of our Patients Through Innovation and the Highest Quality Care


Punctate inner choroidopathy (PIC)



- Young, myopic women in 3rd – 4th decade of life
- Characteristic photopsias
- **Acute/recurrent inflammatory lesions (but no vitritis)**
 - PO steroids, intravitreal steroids, IMT, implants (Yutiq, Retisert)
- **CNVM sequelae**
 - Anti-VEGF

Saving Sight and Improving the Lives of our Patients Through Innovation and the Highest Quality Care

Case 4 Follow-up




Saving Sight and Improving the Lives of our Patients Through Innovation and the Highest Quality Care

Case 5





43M with blurry VA, floaters, and photopsias OD

20/30
IOP 20
Pigment cell
and debris




Saving Sight and Improving the Lives of our Patients Through Innovation and the Highest Quality Care

Case 5 Photo of normal left eye




Saving Sight and Improving the Lives of our Patients Through Innovation and the Highest Quality Care

Case 5 FAF




Saving Sight and Improving the Lives of our Patients Through Innovation and the Highest Quality Care

Case 5 FA




Saving Sight and Improving the Lives of our Patients Through Innovation and the Highest Quality Care

Case 5 ICGA



Saving Sight and Improving the Lives of our Patients Through Innovation and the Highest Quality Care

Multifocal choroiditis with panuveitis (MCP)



- Creamy active choroidal lesions that progress to pigmented and punched out chorioretinal scars
- Lesions may be slightly **bigger**, more **numerous**, and more **confluent** than those seen in PIC
- Can have anterior and/or vitreous inflammation (MCP) but may not
- Like PIC, can have macular CNVM complications that cause VA loss
- Schlaegal line- equatorial curvilinear streaks of CR lesions

Saving Sight and Improving the Lives of our Patients Through Innovation and the Highest Quality Care

Pattern recognition is important...



Saving Sight and Improving the Lives of our Patients Through Innovation and the Highest Quality Care

...but watch for masquerades!




Saving Sight and Improving the Lives of our Patients Through Innovation and the Highest Quality Care

Systemic disease can mimic white dot syndromes



...and should be identified and treated



Saving Sight and Improving the Lives of our Patients Through Innovation and the Highest Quality Care



TREATMENT MODALITIES

Acute phase treatments



Initial treatments to rapidly control disease at onset

- Oral prednisone
 - High dose 1 mg/kg up to 60mg daily
 - Taper weekly
 - Extensive long-term side effects affecting nearly every organ system
 - Safe in pregnancy
 - Generally highly effective at controlling inflammation
- Topical steroid drops are less effective as disease is mostly posterior


Saving Sight and Improving the Lives of our Patients Through Innovation and the Highest Quality Care

Acute phase treatments



Intravitreal injection options

- Ozurdex (dexamethasone implant)
- Xipere (triamcinolone suprachoroidal)
- Anti-VEGF intravitreal injections
 - Only for CNVM in PIC or MCP



Saving Sight and Improving the Lives of our Patients Through Innovation and the Highest Quality Care

Long-term treatments



Systemic immunosuppression and long-term steroid options

- Iluvien (fluocinolone implant)
 - Lasts for 3 years
- Retisert (surgical implant)
 - Lasts for 5+ years
 - ...but being discontinued
- Systemic immunosuppression
 - Methotrexate (once a week pills)
 - Mycophenolate (daily pills)
 - Adalimumab (biweekly injections)
 - Infliximab, tocilizumab (monthly or bimonthly infusion)



Saving Sight and Improving the Lives of our Patients Through Innovation and the Highest Quality Care

10

Treatments for pregnant patients



Many white dot syndromes affect women of child-bearing age

- Many but not all treatment options are safe in pregnancy
- Oral and injection **steroids** are generally always safe
- **Adalimumab** and **infliximab** and **azathioprine** (less used) also safe to use
- **Anti-VEGF injections** generally avoided in pregnancy
- **Methotrexate** and **mycophenolate** contraindicated in pregnancy

Saving Sight and Improving the Lives of our Patients Through Innovation and the Highest Quality Care

11

Conclusions and summary



- The various white dot syndromes differ in the size and distribution of lesions, patient demographics, and prognosis/outcomes
- Multimodal imaging (OCT, FAF, FA, ICGA) is essential in fully characterizing the different presentations of the white dot syndromes
- Oral steroids are a mainstay of treatment; chronic conditions such as birdshot may require long-term immunosuppression; PIC and MCP can cause secondary CNVM which may require anti-VEGF injections
- Patients w/ white dot syndromes require a full uveitis work-up to rule out masquerade conditions which may require a different treatment approach

Saving Sight and Improving the Lives of our Patients Through Innovation and the Highest Quality Care

12



Thank you for your attention!

Andrew Zheng, MD
 azheng@retinacolorado.com